文献速递眼底病与葡萄膜炎小儿眼科与斜弱视

利用出生特征个体化预测威胁视力的早产儿视网膜病变风险

Individual Risk Prediction for Sight-Threatening Retinopathy of Prematurity Using Birth Characteristics.
PubMed 文献 · JAMA Ophthalmol · 2020-01-01

该回顾性队列研究基于瑞典国家患者登记数据分析7609例筛查早产儿,开发并验证了仅用出生特征预测早产儿视网膜病变(ROP)治疗的个体化模型DIGIROP-Birth。模型在24至30周胎龄婴儿中内部验证AUC为0.90(95%CI 0.89-0.92),美国外部验证AUC为0.87(95%CI 0.84-0.89),欧洲外部验证AUC为0.90(95%CI 0.85-0.95)。

要点

  • DIGIROP-Birth仅用出生特征即可预测ROP治疗风险。
  • 24至30周胎龄婴儿中模型内部验证AUC为0.90。
  • 美国外部验证AUC为0.87,欧洲外部验证AUC为0.90。

核心结论

  • 本研究验证了一个针对24至30周胎龄婴儿的个体化预测模型,可基于出生特征数据实现ROP治疗的早期风险预测。
  • 日龄而非经后龄是ROP治疗时间风险的更好预测变量。
  • 该模型是一个可访问的在线应用,似乎具有可推广性,且检验统计量至少与其他需要纵向新生儿数据的模型相当。

研究设计与样本

  • 回顾性队列研究,分析瑞典国家患者登记中2007年1月1日至2018年8月7日出生并接受ROP筛查的婴儿数据。
  • 采用泊松回归处理时变数据(日龄、胎龄、性别、出生体重及重要交互作用)开发个体化预测模型DIGIROP-Birth。
  • 模型进行内部验证和外部验证(美国与欧洲队列),并与4个已发表的预测模型比较。
  • 共纳入7609例婴儿(54.6%为男孩;平均胎龄28.1周,标准差2.1周;平均出生体重1119克,标准差353克)。

主要发现

  • 7609例婴儿中442例(5.8%)因ROP接受治疗,其中胎龄小于24周的354例中142例(40.1%)接受治疗。
  • 无论胎龄如何,接受ROP治疗的风险在出生后第8至12周升高,此后下降。
  • 24至30周胎龄婴儿中DIGIROP-Birth总体预测能力较高:内部验证AUC为0.90(95%CI 0.89-0.92)。
  • 时间验证AUC为0.94(95%CI 0.90-0.98),美国外部验证AUC为0.87(95%CI 0.84-0.89),欧洲外部验证AUC为0.90(95%CI 0.85-0.95)。
  • DIGIROP-Birth的敏感度、特异度、阳性预测值和阴性预测值在数值上至少与CHOP-ROP、OMA-ROP、WINROP和CO-ROP模型相当,这些模型需要更复杂的出生后数据。

关键数值与推荐

  • 24至30周胎龄婴儿中,DIGIROP-Birth内部验证AUC为0.90(95%CI 0.89-0.92)。
  • 时间验证AUC为0.94(95%CI 0.90-0.98)。
  • 美国外部验证AUC为0.87(95%CI 0.84-0.89)。
  • 欧洲外部验证AUC为0.90(95%CI 0.85-0.95)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: To prevent blindness, repeated infant eye examinations are performed to detect severe retinopathy of prematurity (ROP), yet only a small fraction of those screened need treatment. Early individual risk stratification would improve screening timing and efficiency and potentially reduce the risk of blindness. OBJECTIVES: To create and validate an easy-to-use prediction model using only birth characteristics and to describe a continuous hazard function for ROP treatment. DESIGN, SETTING, AND PARTICIPANTS: In this retrospective cohort study, Swedish National Patient Registry data from infants screened for ROP (born between January 1, 2007, and August 7, 2018) were analyzed with Poisson regression for time-varying data (postnatal age, gestational age [GA], sex, birth weight, and important interactions) to develop an individualized predictive model for ROP treatment (called DIGIROP-Birth [Digital ROP]). The model was validated internally and externally (in US and European cohorts) and compared with 4 published prediction models. MAIN OUTCOMES AND MEASURES: The study outcome was ROP treatment. The measures were estimated momentary and cumulative risks, hazard ratios with 95% CIs, area under the receiver operating characteristic curve (hereinafter referred to as AUC), sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV). RESULTS: Among 7609 infants (54.6% boys; mean [SD] GA, 28.1 [2.1] weeks; mean [SD] birth weight, 1119 [353] g), 442 (5.8%) were treated for ROP, including 142 (40.1%) treated of 354 born at less than 24 gestational weeks. Irrespective of GA, the risk for receiving ROP treatment increased during postnatal weeks 8 through 12 and decreased thereafter. Validations of DIGIROP-Birth for 24 to 30 weeks' GA showed high predictive ability for the model overall (AUC, 0.90 [95% CI, 0.89-0.92] for internal validation, 0.94 [95% CI, 0.90-0.98] for temporal validation, 0.87 [95% CI, 0.84-0.89] for US external validation, and 0.90 [95% CI, 0.85-0.95] for European external validation) by calendar periods and by race/ethnicity. The sensitivity, specificity, PPV, and NPV were numerically at least as high as those obtained from CHOP-ROP (Children's Hospital of Philadelphia-ROP), OMA-ROP (Omaha-ROP), WINROP (weight, insulinlike growth factor 1, neonatal, ROP), and CO-ROP (Colorado-ROP), models requiring more complex postnatal data. CONCLUSIONS AND RELEVANCE: This study validated an individualized prediction model for infants born at 24 to 30 weeks' GA, enabling early risk prediction of ROP treatment based on birth characteristics data. Postnatal age rather than postmenstrual age was a better predictive variable for the temporal risk of ROP treatment. The model is an accessible online application that appears to be generalizable and to have at least as good test statistics as other models requiring longitudinal neonatal data not always readily available to ophthalmologists.

来源:JAMA Ophthalmol,查看原文。版权归原作者所有。

引用

  1. Pivodic A, Hård AL, Löfqvist C, et al. Individual Risk Prediction for Sight-Threatening Retinopathy of Prematurity Using Birth Characteristics. JAMA Ophthalmol. 2020. PMID: 31697330. doi:10.1001/jamaophthalmol.2019.4502

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。